Accelmed Partners, a private equity firm focused on acquiring and investing in US commercial stage, lower middle market HealthTech companies, has closed its oversubscribed second fund, Accelmed Fund II at the fund’s hard cap of $400 million, exceeding its original $300 million target. Fund II received significant backing from new investors globally, including pension funds, insurers, family offices, and high net worth individuals, as well as from existing Accelmed limited partners.
The Fund is designed to build upon Accelmed’s strong track record of capitalising on innovative sector opportunities at a time when the demand for technology-enabled healthcare solutions has never been greater.
Dr Uri Geiger, Founder and Managing Partner of Accelmed, says: “We have built our business on the belief that increasing the conversion of healthcare and technology materially improves individuals’ lives, addresses society’s unmet healthcare needs, and ultimately drives down the cost of healthcare. The strong support Fund II received from a diverse group of institutional investors and prominent family offices is a testament to their confidence in our strategy and ability to identify companies at the nexus of healthcare and innovation and partner with them to drive significant value.”
Source: Private Equity Wire
